The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 25, 2022

Filed:

Mar. 05, 2018
Applicant:

California Institute of Technology, Pasadena, CA (US);

Inventors:

David Reza Mittelstein, Pasadena, CA (US);

Morteza Gharib, Pasadena, CA (US);

Stefanie Heyden, Pasadena, CA (US);

Michael Ortiz, Pasadena, CA (US);

Mikhail G. Shapiro, Pasadena, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 7/00 (2006.01); A61M 37/00 (2006.01); A61B 8/08 (2006.01); A61B 17/3205 (2006.01); A61B 5/055 (2006.01); A61B 18/00 (2006.01); A61B 90/00 (2016.01); A61B 17/00 (2006.01);
U.S. Cl.
CPC ...
A61N 7/00 (2013.01); A61B 8/485 (2013.01); A61M 37/0092 (2013.01); A61B 5/055 (2013.01); A61B 8/5261 (2013.01); A61B 17/3205 (2013.01); A61B 2017/00154 (2013.01); A61B 2018/0066 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00732 (2013.01); A61B 2090/374 (2016.02); A61B 2090/378 (2016.02); A61M 2205/058 (2013.01);
Abstract

Systems and methods for targeting specific cell types by selective application of ultrasonic harmonic excitation at a resonance frequency ('oncotripsy') for the specific cell types are presented. The systems and the methods result in permeabilization, lysis, and/or death of the targeted specific cell types by using ultrasonic harmonic excitations that have a frequency and a pulse duration specifically tuned to disrupt nuclear membranes of the targeted specific cell types by inducing a destructive vibrational response therein while leaving non-targeted cell types intact. Target cells may be neoplastic.


Find Patent Forward Citations

Loading…